Selskabets formål er at udvikle nye lægemidler alene eller i partnerskaber.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | - | -131 t. | 48 t. | -140 t. | 1 | |
CVR: 39308967
Previous names: Integrated biomedical technologies ApS, IBIO TECH ApS
Compared to 998 companies in Forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Comparison is based on industry median values
Companies in the same industry and area
CVR 19352102
CVR 44931885
CVR 44214032
CVR 46354834
CVR 37065226
Company placed under bankruptcy proceedings
Kira Gerber Astakhova left the board
Peter Andreas Nicolai Reumert Wagtmann left the board
Kira Gerber Astakhova left as director
Mads Hartvig Clausen left the board
Peter Andreas Nicolai Reumert Wagtmann registered with 10% ownership
ADT HOLDING ApS registered with 10% ownership
KGAA Holding ApS registered with 33% ownership
Mads Hartvig Clausen joined the board
Anders Dyhr Dombernowsky-Toft left the board
Ved dekret af 28. april 2026 har Sø- og Handelsrettens skifteret taget Aptol Pharma ApS under konkursbehandling. Kurator: Advokat Jacob Smith, August Bournonvilles Passage 1, 1055 København K. Sagsnr. K 847/26-K.
Source: Statstidende — updated daily
companydata.dk